DGAP-News: Biosilu Healthcare AG / Key word(s): Agreement

18.09.2017 / 12:18
The issuer is solely responsible for the content of this announcement.


Biosilu Healthcare AG (Frankfurt) and Glycotope GmbH (Berlin) signed term sheet for the development and commercialization of FSH-GEX(R) (follitropin epsilon) for China.

Frankfurt, September 18, 2017 – The life science company Biosilu Healthcare AG (ISIN DE000A0SMU87), listed on the Munich Stock Exchange, announced today the signing of a term sheet defining the framework of a future license and collaboration agreement between Biosilu Healthcare and Glycotope, a biopharmaceutical company based in Berlin. The framework agreement comprises China including Hong Kong and Macau. Financial details have not been disclosed.
 
FSH is responsible for follicle maturation and is administered during the onset of in‑vitro fertilization (IVF) procedures to induce maturation of multiple oocytes for retrieval. Glycotope’s FSH-GEX(R) (follitropin epsilon) is the first fully human glycooptimized recombinant FSH (follicle-stimulating hormone) expressed in human cells and has successfully completed a phase II study. China is a particularly relevant and large market for female fertility products: The recent relaxation of the so-called “one-child policy” in China has triggered a sharp increase of IVF procedures leading to a further acceleration in the demand of modern recombinant FSH products.
 
“Biosilu’s unique approach aims to provide a fair participation in global innovations to Chinese patients. Key elements of our strategy focus on providing tailored solutions for innovators, like Glycotope, to enter the Chinese and other Asian markets. Offering the potential to conclude a final license and collaboration agreement, this term sheet represents an important milestone to become a reputable player bringing Western innovative and commercially attractive niche market products to China”, said Klaus K. Wilgenbus, Chief Executive Officer of Biosilu Healthcare AG.
 
The Management Board
 
 
 
About Biosilu Healthcare:
Biosilu Healthcare (www.biosilu.com) is a German-Chinese life science company accelerating the development and commercialization of specialty biopharmaceuticals addressing the growing needs of Asian patients. Headquartered in Frankfurt am Main, Germany and with a team in Shanghai, China Biosilu Healthcare acquires rights for innovative products for Asian markets by collaborating with Western biopharmaceutical as well as Asian companies and investors.
 
About Glycotope:
Glycotope, founded in 2000 in Berlin, focuses on the development of innovative immune-oncological products for the treatment of various cancer types using their GlycoBody and GlycoExpress(R) technologies. Glycotope has currently two products in advanced clinical development. The Company’s additional pipeline includes preclinical non-antibody and antibody biopharmaceuticals for various indications.
 
Glycotope’s GlycoExpress(R) (GEX(R)) platform allows glyco-optimization and high yield production of a variety of fully human glycosylated biopharmaceuticals such as antibodies, glycoprotein hormones, coagulation factors and cytokines, and by using a toolbox of glyco-engineered proprietary human cell lines that allow for optimization of a whole series of different determining sugars. In addition, the GEX(R) platform can be used for in-process glycosylation control.


18.09.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Disclaimer

This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG and does not constitute a prospectus of Northern Data AG. The information contained in this press release is not intended to form the basis of any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As with all business and investment matters, please consult qualified professional advice. This release and the information contained herein are not for distribution, directly or indirectly, in or into the United States of America, Canada, Australia or Japan.